{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:03:31Z","timestamp":1781629411526,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Handan Municipal Science and Technology Research and Development Program Project Task","award":["23422083277"],"award-info":[{"award-number":["23422083277"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>White-matter abnormalities are common in phenylketonuria (PKU) and are typically attributed to metabolic hypomyelination or intramyelinic edema. Immune-mediated CNS involvement co-occurring with PKU has rarely been described in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>An 18-year-old male university freshman diagnosed with classical PKU presented with a 3-week history characterized by progressive bilateral lower-limb weakness and gait instability. Cervical spinal magnetic resonance imaging (MRI) revealed intramedullary lesions, indicating possible immune-mediated CNS involvement overlapping PKU. Cerebrospinal fluid (CSF) analysis was acellular but demonstrated positive oligoclonal IgG bands. Notable clinical and radiological improvement was observed following the administration of high-dose intravenous methylprednisolone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis<\/jats:title>\n                    <jats:p>Considering the acute course, brain cord involvement, positive OCB, and steroid responsiveness, an acute immune-mediated CNS lesion overlapping PKU was diagnosed. The symmetric diffusion\u2011restricted brain lesions raised the possibility of concomitant PKU\u2011related intramyelinic edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Treatment<\/jats:title>\n                    <jats:p>High\u2011dose intravenous methylprednisolone (1 g\/day for 3 days) followed by an oral taper was administered, together with strict low\u2011phenylalanine diet and vitamin supplementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome<\/jats:title>\n                    <jats:p>Cognitive slowing and lower\u2011limb weakness improved substantially within 3 weeks. One\u2011month follow\u2011up MRI showed regression of spinal lesions and slight reduction of supratentorial white\u2011matter abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights a potential metabolic\u2013immune overlap in PKU. Positive OCB and steroid\u2011responsive cord lesions support an inflammatory component, while symmetric diffusion\u2011restricted brain lesions suggest concurrent metabolic vulnerability. Longitudinal imaging and metabolic control (serial plasma phenylalanine\/tyrosine, myelin\u2011sensitive MRI metrics) are essential to refine diagnosis and guide the need for disease\u2011modifying therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-025-04613-7","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:26:22Z","timestamp":1767918382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent phenylketonuria and immune-mediated central nervous system involvement: a case report highlighting rare co-occurrence"],"prefix":"10.1186","volume":"26","author":[{"given":"Junjie","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"4","key":"4613_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/BF01802042","volume":"12","author":"D Villasana","year":"1989","unstructured":"Villasana D, Butler IJ, Williams JC, Roongta SM. Neurological deterioration in adult phenylketonuria. J Inherit Metab Dis. 1989;12(4):451\u20137.","journal-title":"J Inherit Metab Dis"},{"key":"4613_CR2","unstructured":"Othman EF, Zaynab O, Hicham W, et al. Dual anti-inflammatory and immunomodulatory effects of clove essential oil and eugenol: targeting neutrophil functions and experimental arthritis. Inflammopharmacology. 2025."},{"issue":"1","key":"4613_CR3","doi-asserted-by":"publisher","first-page":"e70049","DOI":"10.1111\/1756-185X.70049","volume":"28","author":"SK Beke","year":"2025","unstructured":"Beke SK, Kaplan H, \u00d6ney M, Cengiz G. Concurrent phenylketonuria and pyogenic sacroiliitis: A case report highlighting rare Co-Occurrence. Int J Rheum Dis. 2025;28(1):e70049.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"4613_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000458915","volume":"20","author":"JE Ayling","year":"1975","unstructured":"Ayling JE, Helfand GD, Pirson WD. Phenylalanine hydroxylase from human kidney. Enzyme. 1975;20(1):6\u201319.","journal-title":"Enzyme"},{"issue":"4","key":"4613_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1006\/mgme.1999.2880","volume":"67","author":"U Lichter-Konecki","year":"1999","unstructured":"Lichter-Konecki U, Hipke CM, Konecki DS. Human phenylalanine hydroxylase gene expression in kidney and other nonhepatic tissues. Mol Genet Metab. 1999;67(4):308\u201316.","journal-title":"Mol Genet Metab"},{"issue":"Suppl 2","key":"4613_CR6","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1007\/PL00014371","volume":"159","author":"PR Huttenlocher","year":"2000","unstructured":"Huttenlocher PR. The neuropathology of phenylketonuria: human and animal studies. Eur J Pediatr. 2000;159(Suppl 2):S102\u2013106.","journal-title":"Eur J Pediatr"},{"key":"4613_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ymgme.2022.03.012","volume":"136","author":"SF Dobrowolski","year":"2022","unstructured":"Dobrowolski SF, Phua YL, Vockley J, Goetzman E, Blair HC. Phenylketonuria oxidative stress and energy dysregulation: emerging pathophysiological elements provide interventional opportunity. Mol Genet Metab. 2022;136:111\u20137.","journal-title":"Mol Genet Metab"},{"key":"4613_CR8","doi-asserted-by":"crossref","unstructured":"Dobrowolski SF, Phua YL, Sudano C, et al. Phenylalanine hydroxylase deficient phenylketonuria comparative metabolomics identifies energy pathway disruption and oxidative stress. Mol Genet Metab. 2021.","DOI":"10.1016\/j.ymgme.2021.04.002"},{"issue":"Suppl 1","key":"4613_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ymgme.2009.10.005","volume":"99","author":"PJ Anderson","year":"2010","unstructured":"Anderson PJ, Leuzzi V. White matter pathology in phenylketonuria. Mol Genet Metab. 2010;99(Suppl 1):S3\u20139.","journal-title":"Mol Genet Metab"},{"key":"4613_CR10","doi-asserted-by":"publisher","first-page":"107583","DOI":"10.1016\/j.ymgme.2023.107583","volume":"139","author":"V Rovelli","year":"2023","unstructured":"Rovelli V, Longo N. Phenylketonuria and the brain. Mol Genet Metab. 2023;139:107583.","journal-title":"Mol Genet Metab"},{"key":"4613_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1148\/radiol.2421051758","volume":"242","author":"SM Sirrs","year":"2007","unstructured":"Sirrs SM, Laule C, M\u00e4dler B, et al. Normal-appearing white matter in patients with phenylketonuria: water content, Myelin water fraction, and metabolite concentrations. Radiology. 2007;242:236\u201343.","journal-title":"Radiology"},{"key":"4613_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1148\/radiology.201.2.8888233","volume":"201","author":"J Pietz","year":"1996","unstructured":"Pietz J, Kreis R, Schmidt H, Meyding-Lamad\u00e9 UK, Rupp A, Boesch C. Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. Radiology. 1996;201:413\u201320.","journal-title":"Radiology"},{"key":"4613_CR13","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/mrm.21422","volume":"58","author":"P Vermathen","year":"2007","unstructured":"Vermathen P, Robert-Tissot L, Pietz J, Lutz T, Boesch C, Kreis R. Characterization of white matter alterations in phenylketonuria by magnetic resonance relaxometry and diffusion tensor imaging. Magn Reson Med. 2007;58:1145\u201356.","journal-title":"Magn Reson Med"},{"key":"4613_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1148\/radiol.2362040611","volume":"236","author":"K Kono","year":"2005","unstructured":"Kono K, Okano Y, Nakayama K, et al. Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter. Radiology. 2005;236:630\u20136.","journal-title":"Radiology"},{"key":"4613_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/BF01799945","volume":"14","author":"AG Antoshechkin","year":"1991","unstructured":"Antoshechkin AG, Chentsova TV, VYu T, Naritsin DB, Railian GP. Content of phenylalanine, tyrosine and their metabolites in CSF in phenylketonuria. J Inherit Metab Dis. 1991;14:749\u201354.","journal-title":"J Inherit Metab Dis"},{"key":"4613_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1203\/00006450-198209000-00009","volume":"16","author":"HK Berry","year":"1982","unstructured":"Berry HK, Bofinger MK, Hunt MM, Phillips PJ, Guilfoile MB. Reduction of cerebrospinal fluid phenylalanine after oral administration of valine, isoleucine, and leucine. Pediatr Res. 1982;16:751\u20135.","journal-title":"Pediatr Res"},{"key":"4613_CR17","first-page":"197","volume":"43","author":"GW Ratzmann","year":"1984","unstructured":"Ratzmann GW, Grimm U, J\u00e4hrig K, Knapp A. On the brain barrier system function and changes of cerebrospinal fluid concentrations of phenylalanine and tyrosine in human phenylketonuria. Biomed Biochim Acta. 1984;43:197\u2013204.","journal-title":"Biomed Biochim Acta"},{"key":"4613_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ymgme.2013.09.001","volume":"110","author":"M Cleary","year":"2013","unstructured":"Cleary M, Trefz F, Muntau AC, et al. Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes. Mol Genet Metab. 2013;110:418\u201323.","journal-title":"Mol Genet Metab"},{"key":"4613_CR19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/jimd.12049","volume":"42","author":"A Pilotto","year":"2019","unstructured":"Pilotto A, Blau N, Leks E, et al. Cerebrospinal fluid biogenic amines depletion and brain atrophy in adult patients with phenylketonuria. J Inherit Metab Dis. 2019;42:398\u2013406.","journal-title":"J Inherit Metab Dis"},{"key":"4613_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1139\/bcb-2013-0023","volume":"91","author":"KR Simon","year":"2013","unstructured":"Simon KR, Dos Santos RM, Scaini G, et al. DNA damage induced by phenylalanine and its analogue p-chlorophenylalanine in blood and brain of rats subjected to a model of hyperphenylalaninemia. Biochem Cell Biol. 2013;91:319\u201324.","journal-title":"Biochem Cell Biol"},{"key":"4613_CR21","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s11011-021-00780-x","volume":"36","author":"JL Faverzani","year":"2021","unstructured":"Faverzani JL, Steinmetz A, Deon M, et al. L-carnitine protects DNA oxidative damage induced by phenylalanine and its Keto acid derivatives in neural cells: a possible pathomechanism and adjuvant therapy for brain injury in phenylketonuria. Metab Brain Dis. 2021;36:1957\u201368.","journal-title":"Metab Brain Dis"},{"key":"4613_CR22","doi-asserted-by":"publisher","first-page":"108464","DOI":"10.1016\/j.ymgme.2024.108464","volume":"142","author":"F Trefz","year":"2024","unstructured":"Trefz F, Frauendienst-Egger G, Dienel G, et al. Does hyperphenylalaninemia induce brain glucose hypometabolism? Cerebral spinal fluid findings in treated adult phenylketonuric patients. Mol Genet Metab. 2024;142:108464.","journal-title":"Mol Genet Metab"},{"key":"4613_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10545-008-0946-2","volume":"32","author":"FJ van Spronsen","year":"2009","unstructured":"van Spronsen FJ, Hoeksma M, Reijngoud DJ. Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause. J Inherit Metab Dis. 2009;32:46\u201351.","journal-title":"J Inherit Metab Dis"},{"key":"4613_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/BF02436753","volume":"18","author":"GM Knudsen","year":"1995","unstructured":"Knudsen GM, Hasselbalch S, Toft PB, Christensen E, Paulson OB, Lou H. Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. J Inherit Metab Dis. 1995;18:653\u201364.","journal-title":"J Inherit Metab Dis"},{"key":"4613_CR25","unstructured":"\u6c6a\u71d5 \u5218\u6668. \u5f20\u56fd\u8363, \u738b\u7389\u5fe0. \u4ee5\u53d1\u4f5c\u6027\u8fd0\u52a8\u969c\u788d\u548c\u611f\u89c9\u969c\u788d\u4e3a\u4e3b\u8981\u8868\u73b0\u7684\u6210\u4eba\u82ef\u4e19\u916e\u5c3f\u75c71\u4f8b\u62a5\u544a \u4e2d\u98ce\u4e0e\u795e\u7ecf\u75be\u75c5\u6742\u5fd7. 2021;38:68\u20139."},{"key":"4613_CR26","doi-asserted-by":"publisher","first-page":"102801","DOI":"10.1016\/j.autrev.2021.102801","volume":"20","author":"FV Pereira","year":"2021","unstructured":"Pereira FV, Jarry VM, Castro J, Appenzeller S, Reis F. Pediatric inflammatory demyelinating disorders and mimickers: how to differentiate with MRI. Autoimmun Rev. 2021;20:102801.","journal-title":"Autoimmun Rev"},{"key":"4613_CR27","doi-asserted-by":"publisher","first-page":"926023","DOI":"10.3389\/fnins.2022.926023","volume":"16","author":"O Thau-Zuchman","year":"2022","unstructured":"Thau-Zuchman O, Pallier PN, Savelkoul P, Kuipers A, Verkuyl JM, Michael-Titus AT. High phenylalanine concentrations induce demyelination and microglial activation in mouse cerebellar organotypic slices. Front Neurosci. 2022;16:926023.","journal-title":"Front Neurosci"},{"key":"4613_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373.","journal-title":"Lancet Neurol"},{"key":"4613_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40246-022-00398-9","volume":"16","author":"NA Elhawary","year":"2022","unstructured":"Elhawary NA, AlJahdali IA, Abumansour IS, et al. Genetic etiology and clinical challenges of phenylketonuria. Hum Genomics. 2022;16:22.","journal-title":"Hum Genomics"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04613-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04613-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04613-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:20:28Z","timestamp":1781626828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-025-04613-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4613"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04613-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional ethics committee of Handan First Hospital determined that this single-case report is exempt from formal ethical review according to the local policy on retrospective case reports.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for the publication of this case report and any accompanying images, clinical data, and laboratory results was first obtained from the patient\u2019s legal guardian because he was temporarily cognitively impaired; after cognitive recovery he provided his own consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}